Click here to Register

2017 Agenda

  • 8:00 am

  • Registration & Breakfast

    Hosted by:

  • 8:45 am

  • Welcome Message


    Robert Langer, PhD

    David H. Koch Institute Professor, MIT

  • 8:50 am

  • Chair’s Opening Remarks and A Year in Review


    Barbara Lueckel, PhD

    Head of Research and Technologies Partnering, Roche

  • 9:15 am

  • Bioinspirationalist Keynote

    Dr Jeff Karp is a world leader in drug delivery, stem cell therapeutics, and tissue adhesives. He is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology.

    Dr Karp’s work has been selected as one of Popular Mechanic’s “Top 20 New Biotech Breakthroughs that Will Change Medicine” and in 2013 the Institute for Chemical Engineers awarded one of his technologies the Most Innovative Product of the Year.  His work has been recognized by various media outlets including CNN, ABC, Fox News, MSNBC, National Geographic, Popular Science, and the Washington Post. Several of his technologies have formed the foundation for products on the market or under development and for the launch of companies including: Gecko BiomedicalSkintifiqueFrequency Therapeutics, and Alivio Therapeutics.


    Jeffrey Karp, PhD

    Director of the Laboratory for Accelerated Medical Innovation, Brigham and Women’s Hospital

  • 9:50 am

  • Viewpoints on Drug Delivery Partnering Panel: The Voices of Big Pharma, Specialty/Generic Pharma, and Drug Delivery Innovators

    The intent of this panel is to compare and contrast the different needs of and processes used by big pharma and specialty/generic pharma in scouting, and acquiring/licensing and integrating drug delivery technologies.

    Moderator:

    Colin Minchom, PhD, FRPharmS

    Principal CMC Consultant, Cordack

    Panelists:
    Bob Bloder
    Robert Bloder

    VP, Global Business Development, Apotex


    Sesha Neervannan, PhD

    Sr VP, Pharmaceutical Development, Allergan


    Julia Rashba-Step, PhD

    VP, Research & Development and Alliance Management, Phosphorex

    Aaron Schwartz
    Aaron Schwartz

    Director, R&D Innovation Sourcing, Novo Nordisk


    Alex Schwarz, PhD
    VP Early Development, Braeburn Pharmaceuticals
  • 10:30 am

  • Morning Networking Session

  • 11:15 am

  • Advancing Drug Delivery to Benefit Patients: A Camurus Case Study & Partnership Chat

    In this session, Camurus will introduce the FluidCrystal technology and describe the development history of the two most advanced programs, from initiation to present.  The company will also discuss major milestones achieved as well as partner selection and deal structures.

    In the second part of this session, Roche and Camurus will discuss:

    • Selection of the right molecules for lead programs, from a business and technical perspective
    • Importance of partnering to advance the technology
    • Key lessons learned as the technology matures and programs advance through scale-up and clinical development

    Featuring:

    Grégoire Schwach, PhD, MSc

    Head of Drug Delivery, F. Hoffmann-La Roche Ltd


    Fredrik Joabsson

    VP, Business Development and Alliance Management, Camurus

  • 11:45 am

  • Panel: Designing Connected Health Solutions to Drive Outcomes

    Connected health continues to be a hot topic within the drug delivery industry and the potential is compelling. The challenge of delivering value through connected health remains significant, complicated by an evolving regulatory landscape and a volatile reimbursement dynamic. Panelists will discuss their approaches to overcoming the challenges of designing and commercializing connected drug delivery system solutions, which create value and are adopted by the market.

    Moderator:
    Kevin Deane
    Kevin Deane

    EVP Front-End Innovation, Medicom Innovation Partner, a Phillips-Medisize Company

    Panelists:

    Dhairya
    Dhairya Mehta
    Senior Director, Digital Health & Connectivity, Combination Product Device Development, Shire

    Michael Meissner
    Michael Meissner, PhD

    CTO and VP, MED Tech, Device Development Unit, Sanofi

    Paul Upham
    Paul Upham
    Senior Principal, Smart Device Technology Center, Genentech

  • 12:15 pm

  • Non-Invasive Drug Delivery: Overview and Emerging Trends


    Kurt Sedo

    VP, Operations, PharmaCircle

  • 12:35 pm

  • Lunch & Partnering Meetings

  • 1:55 pm
    - 6:15 pm

  • Drug Delivery Technology Presentations in Three Tracks, 6 sessions

    Refreshment Break 4:00 pm – 4:15 pm

    Presenting Companies to Date:

    • Track 1A: Injectable Technologies

      2:00 pm- 4:00 pm

      Companies will present  sustained release, targeting, and drug-conjugate technologies, as well as pre-filled syringes, vials and similar technologies.

      Moderator:


      Matthew Burke, PhD

      Head of Drug Delivery, GSK

      Presenting Companies:
      2:00 pm
      Halozyme Therapeutics, Inc


      Kenneth Schultz, MD

      VP of Innovation, Strategy, and Business Development


      2:15 pm
      Phion Therapeutics Ltd


      Helen McCarthy

      Founder and Chairperson


      2:30 pm
      Oakwood Labs


      Tracy Richey, PhD

      Senior Director, Formulations


      2:45 pm
      Serina Therapeutics


      Randall Moreadith, MD, PhD

      President and CEO


      3:00 pm
      Innocore Pharmaceuticals


      Rob Steendam, PhD

      Chief Technology Officer


      3:15 pm
      pSivida Corporation


      Deb Jorn

      EVP Corporate & Commercial Development


      3:30 pm
      Gerresheimer Medical Systems


      Claudia Petersen

      Global Director Business Development


      3:45 pm
      Cristal Therapeutics

      Cristianne JF Rijcken
      Cristianne JF Rijcken, PhD

      Founder and CSO

    • Refreshment Break

      4:00 pm- 4:15 pm

    • Track 1B: Injectable Technologies

      4:15 pm- 6:15 pm

      Companies will present  sustained release, targeting, and drug-conjugate technologies, as well as pre-filled syringe, vial and similar injection technologies

      Moderator:


      Ulrich Bruggemann

      Head Academics and Innovation, Global Medical Devices Development, Sanofi US

      Presenting Companies:
      4:15 pm
      Stevanato Group


      4:30 pm
      SMC Ltd

      Pete_Evans
      Pete Evans

      Director of Device Development, Oval Medical


      4:45 pm
      Elektrofi

      Daniel Dadon
      Daniel Dadon, PhD

      Director, Scientific Strategy


      5:00 pm
      DelSiTech Ltd


      Cora Griffin

      Business Development Director 


      5:15 pm
      PolyPid

      Noam Emanuel
      Noam Emanuel, PhD

      Chief Technology Officer


      5:30 pm
      Phillips-Medisize

      Kevin Deane
      Kevin Deane

      EVP, Front-End Innovation, Medicom Innovation Partner, a Phillips-Medisize Company


      5:45 pm
      Phosphorex


      Julia Rashba-Step, PhD

      VP, R&D and Alliance Management


      6:00 pm
      Infuseon Therapeutics

      Michael Vogelbaum
      Michael Vogelbaum, MD, PhD

      Co-Founder and CMO

    • Track 2A: Oral Delivery Technologies

      2:00 pm- 4:00 pm

      Companies will present oral delivery technologies such as controlled release, modified release, and bioavailability and/or solubility enhancing technologies.

      Moderator:


      René Holm, PhD

      Head and Scientific Director, Drug Product Development, Liquids and Parenterals, Janssen

      Presenting Companies:
      2:00 pm
      Adare Pharmaceuticals


      Anthony Recupero, PhD

      Senior Director, Business Development


      2:15 pm
      Aprecia Pharmaceuticals

      Lauren Beach
      Lauren Beach, PhD 

      Senior Product Development Scientist

      Kelly Caputo
      Kelly Caputo

      Senior Scientist, Product Development


      2:30 pm
      Evonik Corporation


      Hans Baer, MSc

      Head Global Drug Delivery Orals


      2:45 pm
      leon-nanodrugs

      Wolfgang Beier
      Wolfgang Beier, PhD

      Co-founder and CSO


      3:00 pm
      DS Technology


      Elke Sternberger-Rützel, PhD

      Scientific Director


      3:15 pm
      Intract Pharma


      3:30 pm
      iCeutica

      Jason Coleman
      Jason Coleman, PhD

      Associate Director of Pharmaceutical R&D


      3:45 pm
      Capsugel

      Aaron Stewart
      Aaron Stewart 

      Senior Scientist 

    • Refreshment Break

      4:00 pm- 4:15 pm

    • Track 2B: Ophthalmic, Transdermal & Transmucosal Technologies & Devices

      4:15 pm- 6:15 pm

      Companies will present transdermal, pulmonary, nasal, ophthalmic, and other mucosal formulation and device technologies.

      Moderator:


      Robert Saklatvala, PhD

      Director, Discovery Pharmaceutical Sciences, Merck

      Presenting Companies:
      4:15 pm
      LayerBio


      Ken Mandell, MD, PhD

      CEO and Founder


      4:30 pm
      Exicure


      David Giljohann, PhD

      CEO


      4:45 pm
      Novaflux, Inc

      Sandeep Kathju
      Sandeep Kathju, PhD

      CMO

      Mohamed Labib
      Mohamed Labib, PhD

      CEO


      5:00 pm
      Ocular Therapeutix


      5:15 pm
      Suono Bio

      Carl Schoellhammer
      Carl Schoellhammer

      Co-founder


      5:30 pm
      Vaxess Technologies

      Michael Schrader
      Michael Schrader
      CEO 

      Two spots available!

    • Track 3A: Device Technologies

      2:00 pm- 4:00 pm

      Companies will present various technologies such as needle-free devices, autoinjectors, patch pumps/wearable injectors, and other novel delivery devices.

      Moderator:


      Mathias Romacker

      Senior Director, Device Strategy, Pfizer

      Presenting Companies:
      2:00 pm
      Insulet Corporation


      Michael Graffeo

      VP, Business Development, Drug Delivery


      2:15 pm
      Portal Instruments


      Patrick Anquetil

      CEO


      2:30 pm
      Enable Injections


      Mike Hooven

      President and CEO


      2:45 pm
      Credence MedSystems


      John Merhige

      Chief Commercial Officer


      3:00 pm
      West Pharmaceutical Services

      Carl Dabruzzi
      Carl Dabruzzi

      Senior Manager, Product Management, Self Injection Systems


      3:15 pm
      Bespak


      Steven Kaufman

      Global Business Development Lead


      3:30 pm
      Sensile Medical


      Gerhard Mayer, PhD

      VP, Business Development


      3:45 pm
      BioCorp


      Eric Dessertenne

      CEO

    • Refreshment Break

      4:00 pm- 4:15 pm

    • Track 3B: Device Technologies

      4:15 pm- 6:15 pm

      Companies will present various technologies such as needle-free devices, autoinjectors, patch pumps/wearable injectors, and other novel delivery devices.

      Moderator:

      Justin Wright
      Justin Wright, PhD

      VP, Drug Delivery Innovation, DDR&D Technology, Eli Lilly & Co

      Presenting Companies:
      4:15 pm
      Nemera

      Isabelle Delcroix
      Isabelle Delcroix    
      Strategy Director 

      4:30 pm
      Mitsubishi Gas Chemical


      Takuya Minezaki

      Senior Researcher


      4:45 pm
      BD Medical

      Janice Adkins
      Janice Adkins

      Associate Director, Marketing


      5:00 pm
      Cambridge Design Partnership


      Uri Baruch

      Head of Drug Delivery


      5:15 pm
      Vernay


      Paul Pankhurst
      Founder & CEO

      5:30 pm
      DALI Medical Devices


      David Daily, MSc, MBA

      Co-founder and CEO


      5:45 pm
      Windgap Medical, Inc

      Brent Buchine
      Brent Buchine, PhD

      Co-founder and CTO


      6:00 pm
      Flowonix Medical Inc

  • 6:15 pm

  • End of Day One & Annual Networking Reception

2017 Agenda

  • 7:45 am

  • Partnering Meetings Begin

  • 8:00 am

  • Breakfast

  • 8:45 am

  • Chair’s Welcome Address


    Barbara Lueckel, PhD

    Head of Research and Technologies Partnering, Roche

  • 9:00 am

  • CEO Keynote Fireside Chat


    Lars Rebien Sorensen

    Former President and CEO, Novo Nordisk
    Ranked as the world’s top performing CEO in 2015 and 2016 by Harvard Business Review

    with


    Barbara Lueckel, PhD

    Head of Research and Technologies PartneringRoche

  • 9:30 am

  • Nanotechnology Keynote

    Dr Omid Farokhzad is an inventor of more than 145 issued / pending patents. These technologies have formed the basis for the launch of four biotechnology companies: BIND Therapeutics (acquired by Pfizer), Selecta Biosciences, Tarveda Therapeutics (formerly Blend Therapeutics) and Placon Therapeutics (spin-out from Tarveda), which are translating the aforementioned academic innovations toward commercialization and societal impact. Dr Farokhzad has served in various capacities on the Board of Directors and the Scientific Advisory Board of these companies.

    In his lecture, Dr Farokhzad will be focusing on the emerging understanding of the nano-bio interactions and its implications for developing safer and more effective therapeutic and diagnostic modalities. Nanotechnology enabled drug delivery approaches for predictive and personalized medicines will be discussed with emphasis on the lessons that have been learned during their bench-to-bedside translation.

    Omid Farokhzad
    Omid Farokhzad, MD
    Professor, Harvard Medical School, Center for Nanomedicine and Director, Brigham and Women’s Hospital

    Named One of the 100 Most Influential People in Biotech by Scientific American

  • 10:00 am

  • Panel: Utilizing a Device Platform Technology across Multiple Therapeutic Categories

    Most pharma and biotech companies realize the need and benefit of having a platform device technology. The challenge then becomes figuring out how to utilize the device to deliver different types of drugs for various indications such as rheumatoid arthritis, cancer, and rare diseases.

    Moderator:
    Paul Jansen
    Paul Jansen

    Former Associate VP / Board Member & Senior Advisor, Sanofi / Haselmeier

    Panelists:

    Donna French, PhD
    VP, Drug Delivery & Device Development, MedImmune


    Michael Graffeo

    VP, Business Development, Drug Delivery, Insulet


    Rajan Patel

    CEO, iO Lifescience


    Srini Sridharan, PhD

    Group Director, Materials Science & Engineering, BMS

  • 10:40 am

  • Morning Networking Session

  • 11:25 am

  • 7th Annual Company Spotlights

    In this session, we highlight three companies to discuss their partnering philosophy, current needs and scouting interests, as related to drug delivery.

    Boehringer Ingelheim

    Keith Horspool, PhD

    VP, Pharmaceutics

    Novartis Institutes for Biomedical Research

    Manuel Sanchez-Felix, PhD

    Senior Fellow, Novel Drug Delivery Technologies

    Novo Nordisk
    Speaker TBA

  • 12:10 pm

  • A Pharma View on Some of the Challenges with Drug Delivery Technical Development


    Grégoire Schwach

    Head of Drug Delivery, F. Hoffmann-La Roche Ltd

  • 12:30 pm

  • Luncheon Roundtable Session & Partnering Meetings

    Advancing the Discovery and Development of Oligonuleotide Therapeutics
    The PODD Luncheon Roundtable is open to all delegates and features a dedicated moderator. The optional roundtable is an excellent way to engage in in-depth discussions and meet colleagues with similar interests.

    Be sure to pick up a Grab-and-Go lunch at 12:30pm and join the discussion.

    Presented by:

    Advancing the Discovery and Development of Oligonuleotide Therapeutics

    Moderator:
    marian gindy
    Marian Gindy, PhD

    Executive Director, Pharmaceutical Sciences, Merck 

  • 1:30 pm

  • Current and Emerging Drug Delivery Needs in Oncology

    Due to the increasing number of parenteral biologic therapies that are administered intravenously, the already high pressure on infusion capacity and healthcare resources is expected to further increase. A change from intravenous to subcutaneous dosing has been shown to reduce dosing complexity and overall drug administration related costs. There is keen interest in technologies that facilitate subcutaneous administration and potentially enable drug administration in the home setting.

    Led by:

    Beate Bittner, PhD

    Portfolio Strategy Director, Roche

    Panelists:

    Janice Adkins
    Janice Adkins

    Associate Director, Marketing, BD Medical – Pharmaceutical Systems, North America / EMEA


    Ulrich Bruggemann

    Head Academics and Innovation, Global Medical Devices Development, Sanofi US


    Shawn Davis, PhD

    Director, Technology Strategy & Innovation, Amgen

    Declan Reilly
    Declan Reilly

    Section Head, Device Engineering, Device Development PTDE-D, Roche


    Andrew J Yee, MD

    Medical Oncologist, Massachusetts General Hospital Cancer Center

  • 2:30 pm

  • DDS Technology Soapbox

    sponsored by

    This session features five minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up companies, entrepreneurs, inventors, licensing officers and university researchers.

    Moderator:

    Patrick Lim Soo, PhD

    Senior Principal Scientist, Novel Delivery Technologies, Pfizer

    Presenters:
    Sonoran Biosciences

    Joseph Cooper
    Joe Cooper

    Chief Business Officer

    Subcuject

    Paul Jansen
    Paul Jansen

    Board Member

    BioHealthWays, Inc

    Brian Pan
    Brian Pan

    CEO and Co-founder

    Taithera, Inc

    Seth Harlem
    Seth Harlem

    Co-founder and CEO

    Vesselon

    Rhodemann Li
    Rhodemann Li

    Founder, EVP Strategy & Finance

    Pendant Biosciences

    Eric Elmquis
    Eric Elmquist, PhD

    VP, Research & Development

    Additional presenters TBA

  • 3:15 pm

  • Panel: Hitting the "Reset" Button on Direct-to-CNS Delivery

    The expert panel will address the scientific and business challenges and opportunities in this space. Panelists will discuss the difficult nature of providing therapies for diseases of the CNS, covering both device and chemistry-enabled technologies. They will also address questions such as:

    • Can devices take us where chemistry has not?
    • What advances are being made in the field of chemistry conjugation technologies?
    • Why is intrathecal, intracerebroventricular and intraparenchymal delivery relevant for CNS and other therapeutic categories?

    Finally, the panel will talk about lessons learned, particularly with regard to scientific vs. business rationale.

    Introduction by:

    PJ Anand
    Founder and CEO, Alcyone Lifesciences

    Moderator:

    Lisa Shafer, PhD

    Senior Director, New Devices and Bioelectronic Technologies, Teva

    Panelists:

    Dan Abrams
    Dan Abrams, MD
    CEO, Cerebral Therapeutics, LLC

    Krystof Bankiewicz
    Krystof Bankiewicz, MD, PhD

    Director, Interventional Neuro Center, UCSF

    Mikhail Papisov
    Mikhail Papisov, PhD

    Associate Professor, Harvard Medical School & Massachusetts General Hospital 


    Lamya Shihabuddin, PhD

    Cluster Head, Neuro Rare Diseases, Shire

  • 4:00 pm

  • Addressing R&D Challenges using Drug Delivery Technologies

    The expert panel of scientific leaders from industry will discuss current formulation and delivery challenges in the R&D pipeline. Each panelist will address a specific disease area from ophthalmic diseases, diabetes, oncology, autoimmune disorders, and neurodegenerative diseases and discuss the role of drug delivery in the treatment of disease. The panel will also cover currently available delivery technologies and where improvement is needed.

    Moderator:

    Ann Daugherty, PhD

    Senior Manager, Drug Delivery, Genentech

    Panelists:

    Marianne-Ashford
    Marianne Ashford, PhD
    Senior Principal Scientist, Pharmaceutical Sciences, AstraZeneca

    Advait Badkar
    Advait Badkar, PhD

    Senior Director, Novel Delivery Technologies, BioTherapeutics, Pfizer

    marian gindy
    Marian Gindy, PhD
    Executive Director, Pharmaceutical Sciences, Merck 

    Kapil Gupta
    Kapil Gupta, PhD
    Associate Director, Protein Pharmaceutical Development, Biogen

  • 4:45 pm

  • Conference Concludes